0001140361-17-010973.txt : 20170308
0001140361-17-010973.hdr.sgml : 20170308
20170308115130
ACCESSION NUMBER: 0001140361-17-010973
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170306
FILED AS OF DATE: 20170308
DATE AS OF CHANGE: 20170308
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: NEVRO CORP
CENTRAL INDEX KEY: 0001444380
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
IRS NUMBER: 562568057
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1800 BRIDGE PARKWAY
CITY: REDWOOD CITY
STATE: CA
ZIP: 94065
BUSINESS PHONE: 650-251-0005
MAIL ADDRESS:
STREET 1: 1800 BRIDGE PARKWAY
CITY: REDWOOD CITY
STATE: CA
ZIP: 94065
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Enxing Michael
CENTRAL INDEX KEY: 0001622421
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36715
FILM NUMBER: 17674341
MAIL ADDRESS:
STREET 1: C/O NEVRO CORP.
STREET 2: 4040 CAMPBELL AVE.
CITY: MENLO PARK
STATE: CA
ZIP: 94025
4
1
doc1.xml
FORM 4
X0306
4
2017-03-06
0
0001444380
NEVRO CORP
NVRO
0001622421
Enxing Michael
C/O NEVRO CORP.
1800 BRIDGE PARKWAY
REDWOOD CITY
CA
94065
0
1
0
0
VP of Sales
Common Stock
2017-03-06
4
S
0
37000
90.989
D
40463
D
Common Stock
2017-03-06
4
M
0
1500
3.60
A
41963
D
Common Stock
2017-03-06
4
S
0
800
90.9038
D
41163
D
Common Stock
2017-03-06
4
S
0
600
92.3533
D
40563
D
Common Stock
2017-03-06
4
S
0
100
92.85
D
40463
D
Stock Option (Right to Buy)
3.60
2017-03-06
4
M
0
1500
0.00
D
2022-12-17
Common Stock
1500
38608
D
The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
Includes 2,500 restricted stock units.
The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $90.80 to $91.13, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $91.81 to $92.71, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
100% of the shares subject to the option are fully vested and exercisable.
/s/ Andrew Galligan, as Attorney-in-Fact for Michael Enxing
2017-03-08